Skip to main content

Advertisement

SpringerLink
Log in

Diabetes, vascular complications and antiplatelet therapy: open problems

  • Review Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Diabetes mellitus is commonly associated with both microvascular and macrovascular complications (coronary artery disease, cerebrovascular events, severe peripheral vascular disease, nephropathy and retinopathy). There is wide evidence demonstrating that platelet degranulation and synthesis of TxA2 are increased in diabetic patients. For this reason, many studies on anti-platelet therapy have been made to reduce thrombotic complication of diabetes mellitus. Some diabetic patients, although treated with ASA, have a high prevalence of recurrent thrombotic events, which may presumably be due to an “ASA resistance”. Nevertheless, this drug remains the one with the greatest benefit. To optimize its function, we should try to understand the causes of “aspirin resistance”, try to find the most suitable dosage, recommending patients to comply constantly with the prescription given and to avoid interactions with other drugs. “Clopidogrel resistance” is a term not clearly defined. The clinical implications of “clopidogrel resistance” are unknown. An important consideration affecting the use of aspirin in diabetic patients is its interaction with ACE-inhibitors. Another question is antiplatelet therapy in nephropathic diabetic patients. Although these patients are at high thrombotic and haemorrhagic risk, they should nevertheless be considered eligible to undergo antithrombotic therapy, taking into account the individual’s haemorrhagic risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Luscher TF, Creager MA, Beckman JA, Casentino F (2003) Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy. Circulation 108:1655–1661

    Article  PubMed  Google Scholar 

  2. Stamler J, Vaccaro O, Neaton JD, Wentwort D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434–444

    Article  PubMed  CAS  Google Scholar 

  3. Nesto RW (2004) Correlation between cardiovascular disease and diabetes mellitus current concepts. Am J Med 116(5):11S–22S

    Article  PubMed  Google Scholar 

  4. UKPDS Group (1990) UK Prospective Diabetes Study 6: complications in newly diagnosed type II diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 13:1–11

    Google Scholar 

  5. Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570–2581

    Article  PubMed  CAS  Google Scholar 

  6. Watala C (2005) Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 11:2331–2365

    Article  PubMed  CAS  Google Scholar 

  7. Colwell JA, Winocour PD, Halushka PV (1983) Do platelets have anything to do with diabetic microvascular disease? Diabetes 32(Suppl 2):14–19

    PubMed  Google Scholar 

  8. Ferroni P, Basili S, Falco A, Davi G (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2:1282–1291

    Article  PubMed  CAS  Google Scholar 

  9. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C (2001) Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769–1774

    Article  Google Scholar 

  10. Bridges JM, Dalby AM, Millar JHD, Weaver JA (1965) An effect of d-glucose on platelet stickiness. Lancet 1:75–77

    Article  PubMed  CAS  Google Scholar 

  11. D’Angelo A, Micossi P, Mannucci PM, Garimberti P, Franchi F, Pozza G (1984) Increased production of platelet thromboxane B2 in non-insulin-dependent diabetes: relationship to vascular complications. Eur J Clin Invest 14:83–86

    Article  PubMed  Google Scholar 

  12. Watala C, Boncler M, Gresner P (2005) Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 57(Suppl):42–58

    Google Scholar 

  13. Oskarsson HJ, Hofmeyer TG (1996) Platelet from diabetic patients with diabetes mellitus have impaired ability to mediate vasodilatation. J Am Coll Cardiol 27:1464–1470

    Article  PubMed  CAS  Google Scholar 

  14. Davi G, Belvedere M, Vigneri S, Catalano I, Giammarresi C, Roccaforte S, Consoli A, Mezzetti A (1996) Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. Thromb Haemost 76:34–37

    PubMed  CAS  Google Scholar 

  15. Michelson AD, Cattaneo M et al (2005) Aspirin-resistance: position paper of the working group on aspirin resistance. J Thromb Haemost 3:1309–1311

    Article  PubMed  CAS  Google Scholar 

  16. Di Minno G, Silver MJ, Cerbone AM, Murphy S (1986) Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68:886–891

    CAS  Google Scholar 

  17. Gerrard JM, Stuart MJ, Rao GHR, Steffes MW, Mauer SM, Brown DM, White JG (1980) Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J Lab Clin Med 95:950–958

    PubMed  CAS  Google Scholar 

  18. Jokl R, Colwell JA (1997) Arterial thrombosis and atherosclerosis in diabetes. Diabetes Metab Rev 5:1–15

    Google Scholar 

  19. Colwell JA, Nesto RW (2003) The platelets in diabetes. Diabetes Care 26:2181–2188

    Article  PubMed  Google Scholar 

  20. ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. J Am Med Assoc 268:1292–1300

    Article  Google Scholar 

  21. Antiplatelet trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various category of patients. Br Med J 308:81–106

    Google Scholar 

  22. Antithrombotic Trialist’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J 324:71–86

    Article  Google Scholar 

  23. ISIS 2 (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS–2. ISIS-2 (Second International Study Of Infarct Survival) collaborative group. Lancet 2:349–360

    Google Scholar 

  24. Colwell JA (1997) Aspirin therapy in diabetes. Diabetes Care 20:1767–1771

    PubMed  CAS  Google Scholar 

  25. Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321:129–135

    Google Scholar 

  26. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S (1998) Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial: HOT study group. Lancet 351:1755–1762

    Article  PubMed  CAS  Google Scholar 

  27. Collaborative group of the Primary Prevention Project (2001) Low dose aspirin and vit E in people at cardiovascular risk: a randomized trial in general practice. Lancet 357:89–95

    Article  Google Scholar 

  28. Sacco M, Pellegrini F, Roncaglioni MC, Venzini F, Tognoli G, Nicolucci A (2003) On behalf of the PPP collaborative group primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care 26:3264–3272

    Article  PubMed  CAS  Google Scholar 

  29. Arjomand HA, Roukoz B, Surabhi SK, Cohen M (2003) Platelets and antiplatelet therapy in patients with diabetes mellitus. J Invasive cardiol 15:264–269

    PubMed  Google Scholar 

  30. Buse JB et al (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 30:162–172

    Article  PubMed  CAS  Google Scholar 

  31. Buse JB et al (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus. Circulation 115:114–126

    Article  PubMed  Google Scholar 

  32. American Diabetic Association Position Statement (2000) Aspirin therapy in diabetes. Diabetes Care 23:61S–62S

    Google Scholar 

  33. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases (AHA scientific statement). Circulation 106:388–391

    Article  PubMed  Google Scholar 

  34. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ (2002) Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90:625–628

    Article  PubMed  Google Scholar 

  35. TIMAD Study Group (1990) Ticlopidine treatment reduces the progression of non proliferative diabetic retinopathy. Arch Ophtalmol 108:1577–1583

    Google Scholar 

  36. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339

    Article  Google Scholar 

  37. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Duntz KM, Hunink MG, Goldman L (2002) Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary artery disease. N Engl J Med 346:1819–1821

    Article  Google Scholar 

  38. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502

    Article  Google Scholar 

  39. American College of Cardiology website: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: unstable angina/non-ST elevation myocardial infarction. Available at http://www.acc.org. Accessed 29 Sept 2002

  40. Davi G, Patrono C, Catalano I, Custro N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A (1993) Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. Arterioscler Thromb 13:1346–1349

    PubMed  CAS  Google Scholar 

  41. Giustina A, Perini P, Desenzani P, Bossoni S, Ianniello P, Milani M, Davi G, Romanelli G (1998) Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 47:423–430

    Article  PubMed  CAS  Google Scholar 

  42. Neri-Serneri GG, Coccheri S, Marubini E, Violi F (2004) For the committees and the investigators of the drug evaluation in atherosclerotic vascular disease in diabetics (DAVID) study group. Eur Heart J 25:1845–1852

    Article  PubMed  CAS  Google Scholar 

  43. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C et al (2001) Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndrome. Circulation 104:2767–2771

    Article  PubMed  CAS  Google Scholar 

  44. Bhatt DL, Marso SP, Lincoff M et al (2000) Abxicimab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 35:922–928

    Article  PubMed  CAS  Google Scholar 

  45. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 126:234S–264S

    Article  PubMed  CAS  Google Scholar 

  46. Gum PA, Kottke-Marchant K, Welsh PA et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961–965

    Article  PubMed  CAS  Google Scholar 

  47. Sanderson S, Emery J, Baglin T, Kinmonth AL (2005) Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 142:370–380

    PubMed  CAS  Google Scholar 

  48. Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Di Renzo L, Violi F (2005) Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 3:2784–2789

    Article  PubMed  CAS  Google Scholar 

  49. Hanjis C, Frishman WH, Lerner RG (2006) Aspirin resistance: mechanisms and clinical implications. Cardiol Rev 14(1):18–25

    Article  PubMed  Google Scholar 

  50. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB (2006) Comparison of aspirin resistance in type I versus type 2 diabetes mellitus. Am J Cardiol 97:567–570

    Article  PubMed  CAS  Google Scholar 

  51. Di Minno G, Violi F (2004) Aspirin resistance and diabetic angiopathy: back to the future. Thromb Res 113:97–99

    Article  PubMed  CAS  Google Scholar 

  52. Watala C, Golanski J, Pluta J, Boncler M, rozalski M, Luzak B, Kropiwnicka A, Drzewoski J (2004) Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)—its relation to metabolic control. Thromb Res 113:101–113

    Article  PubMed  CAS  Google Scholar 

  53. Drezewoski J, Watala C (2004) Is aspirin resistance a real problem in people with type 2 diabetes? Diabetes Care 27(5):1245–1246

    Article  Google Scholar 

  54. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, Drzewoski J (2005) Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83:148–158

    Article  PubMed  CAS  Google Scholar 

  55. Friend M, Vucenik I, Miller M (2003) Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 326:82–83

    Article  PubMed  Google Scholar 

  56. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F et al (1997) In vivo formation of 8-Epi- prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 17:3230–3235

    PubMed  CAS  Google Scholar 

  57. Biondi-Zoccai GG, Abbate A, Liuzzo G et al (2003) Atherothrombosis, inflammation and diabetes. J Am Coll Cardiol 41:1071–1077

    Article  PubMed  CAS  Google Scholar 

  58. Meade TW, Brennan PJ (2000) Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 321:13–17

    Article  PubMed  CAS  Google Scholar 

  59. Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817

    Article  PubMed  CAS  Google Scholar 

  60. Lau WC, Waskell LA, Watkins PB et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet activation: a new drug–drug interaction. Circulation 107:32–37

    Article  PubMed  CAS  Google Scholar 

  61. Michos ED, Ardehali R, Blumenthal RS, Lange RA, Ardehali H (2006) Aspirin and clopidogrel resistance. Mayo Clin Proc 81(4):518–526

    Article  PubMed  CAS  Google Scholar 

  62. Nguyen TA, Diodati JG, Pharard C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45:1157–1164

    Article  PubMed  CAS  Google Scholar 

  63. Angiolillo DJ, Bernardo E, Ramirez C et al (2006) Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48:298–304

    Article  PubMed  CAS  Google Scholar 

  64. Sibbing D et al (2006) Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. J Thromb Haemost 4:2566–2568

    Article  PubMed  CAS  Google Scholar 

  65. Angiolillo DJ et al (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 11:708–716

    Article  CAS  Google Scholar 

  66. Coccheri S (2007) Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 67(7):997–1026

    Article  PubMed  CAS  Google Scholar 

  67. Stys T, Lawson WE, Smaldone G, Sys A (2000) Does aspirin attenuate the beneficial effects of angiotensin converting enzyme inhibition in heart failure? Arch Int Med 160:1409–1413

    Article  CAS  Google Scholar 

  68. Leor J, Reicher-Reiss H, Goldbourt U, Boyko V, Gottlieb S, Battler A, Behar S (1999) Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 33:1920–1925

    Article  PubMed  CAS  Google Scholar 

  69. Dineen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Int Med 157:1413–1418

    Article  Google Scholar 

  70. Sowers JR, Epstein M (1995) Diabetes mellitus and associated hypertension, vascular disease and nephropathy. Hypertension 26:869–879

    PubMed  CAS  Google Scholar 

  71. Trovati M, Cavalot F (2004) Optimization of hypolipidemic and antiplatelet treatment in the diabetic patient with renal disease. J Am Soc Nephrol 15:S12–S20

    Article  PubMed  CAS  Google Scholar 

  72. Sagedal S, Hartmann A, Sundstramk BjornsenS, Brosstad F (2001) Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 16:987–993

    Article  PubMed  CAS  Google Scholar 

  73. Steiner RW, Coffins C, Carvalho AD (1979) Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Haematol 7:107–117

    Article  CAS  Google Scholar 

  74. Di Minno G, Martinez J, McKean ML et al (1985) Platelet dysfunction in uremia. Am J Med 79:552–559

    Article  PubMed  CAS  Google Scholar 

  75. Evans EP, Branch RA, Bloom AL (1972) A clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol 25:745–753

    Article  PubMed  CAS  Google Scholar 

  76. Boccardo P, Remuzzi G, Galbusera M (2004) Platelet dysfunction in renal failure. Semin Thromb Hemost 30:579–589

    Article  PubMed  CAS  Google Scholar 

  77. Livio M, Benigni A, Vigano G et al (1986) Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1:414–416

    Article  PubMed  CAS  Google Scholar 

  78. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB (2002) Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Am Int Med 137:555–562

    Google Scholar 

  79. Reddan DN (2002) Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate cautions or the absence of data. Am Heart J 144:206–207

    Article  PubMed  Google Scholar 

  80. Bulatova NR, MF Yousef A, AbuRuz SM (2007) Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus. Thromb Res 121:43–50

    Article  PubMed  CAS  Google Scholar 

  81. Srikanth S, Deedwania P (2005) Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach. Cardiol Clin 23:193–210

    Article  PubMed  Google Scholar 

  82. Smith SC, Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. JACC 47:2130–2139

    PubMed  Google Scholar 

  83. Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G, Nicolucci A (2005) Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 93:8–16

    PubMed  CAS  Google Scholar 

  84. Ikonomidis I, Lekakis J, Vamvakon G, Andreotti F, Nihoyannopulos P (2005) Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with coronary artery disease: effects of aspirin treatment. Am Heart J 149:832–839

    Article  PubMed  CAS  Google Scholar 

  85. Wong S, Morel- Kopp MC, Chen Q, Appleberg M, Ward CM, Lewis DR (2006) Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease. Thromb Haemost 95:1042–1043

    PubMed  CAS  Google Scholar 

  86. American Diabetes Association (2002) Clinical practice recommendations 2002, aspirin therapy in diabetes. Diabetes Care 25(Suppl 1):S78–S79

    Google Scholar 

  87. Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P (2006) Dose and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95:652–658

    PubMed  CAS  Google Scholar 

  88. Takahashi J, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H, Shibano T, Watanabe G, Ikeda Y, Murata M (2007) Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb. Res 119:517–524

    CAS  Google Scholar 

  89. Nowak SU, Jaber LA (2003) Aspirin dose for prevention of cardiovascular disease in diabetics. Am Pharmacother 37:116–121

    Article  CAS  Google Scholar 

  90. Colwell JA (2005) Is aspirin effective in diabetic patients? Yes. J Thromb Haemost 3:2612–2614

    Article  PubMed  CAS  Google Scholar 

  91. Cimminiello C (2005) Is aspirin effective in diabetic patients? No. J Thromb Haemost 3:2615–2616

    Article  PubMed  CAS  Google Scholar 

  92. Abaci A, Yilmaz Y, Caliskan M, Bayram F, Cetin M, Unal A, Cetin S (2005) Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res 2005(116):465–470

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, “Federico II” University Hospital, Via S. Pansini 5 Edificio 1, 80131, Naples, Italy

    A. M. Cerbone, N. Macarone-Palmieri, G. Saldalamacchia, A. Coppola, G. Di Minno & A. A. Rivellese

Authors
  1. A. M. Cerbone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Macarone-Palmieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Saldalamacchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Coppola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Di Minno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. A. Rivellese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. M. Cerbone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cerbone, A.M., Macarone-Palmieri, N., Saldalamacchia, G. et al. Diabetes, vascular complications and antiplatelet therapy: open problems. Acta Diabetol 46, 253–261 (2009). https://doi.org/10.1007/s00592-008-0079-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-008-0079-y

Keywords

Search

Navigation